SENS.L Regulatory News (SENS)

Directorate Change

Sensyne Health plc (LSE: SENS) ("Company"), the British clinical AI technology company, announces that, further to the Board change announcement made by the Company on 4 October 2019, Non-Executive Chairman Charles Swingland has informed the Board of his intention not to seek re-election at the Company's Annual General Meeting ("AGM") today due to continued ill health and he will step down as a Director at the conclusion of the AGM.

As a consequence, Resolution 10 as set out in the AGM Notice has been withdrawn.

Commenting on the announcement, Dr Annalisa Jenkins, Acting Chairman, said:

"On behalf of the Board, I would like to wish Charles a full recovery and thank him for his contribution to the Company."

-ENDS-

For more information please contact:

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com